AstraZeneca Allemansfond

The fund is actively managed special fund (non-UCITS) and thereby the fund deviates from a UCITS fund by concentrating holdings to a smaller number of equities issued by companies in primarily Sweden. The fund invests a significant amount (maximum of 50% of assets) in AstraZeneca. The fund is reported as an Article 8 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).

Performance

0	3.	07	'.2	02	4


YTD	1 week	1 mth.	3 mån	1 year	5 years	10 years
15.44%	-0.82%	-2.03%	6.76%	16.30%	111.58%	288.28%

Average performance

Average. perf.	2 years	3 years	5 years	10 years
Fund ¹	18.24%	14.51%	16.55%	14.91%
Index ²	17.68%	11.44%	-	-

¹ Calculated on the fund's monthly closing price

Five years performance



Portfolio



Fund performance was favorable during Q1 2024 and the fund rose just over 9% in SEK. The upturns in the equity market were primarily driven by an increased confidence in a soft landing of the economy that is supported by expected rate cuts.

The strongest contributors to fund returns were Astra Zeneca, Volvo and SEB, where Astra Zeneca rebounded after declining on the reporting date in the wake of higher than expected costs. Volvo posted strength in line with the rest of the manufacturing sector and SEB announced a share buyback program in conjunction with its quarterly report, which was received positively by the market.

Nibe and Sweco, which were weighed down by reports that were weaker than expected, had the most negative impact on returns. Nibe's sales were negatively affected by the persistently high inventories of heating pumps in the distribution chain that were accumulated during a period of high expectations for further strong growth

Fund manager



Ulrika Orstadius

Experience in the fund industry 2011. Portfolio Manager since 1 November 2022.

Main category Equity Fund

Risk 4

Rate 4069.12 (03.07.2024)

Reporting Currency SEK

Price/Trade Daily

Total Rating $^{\text{TM}}$

Minimum investment0 SEKMonthly savings0 SEKTraded on the InternetNoManagement Fee0.9%Entry charge0%Exit charge0%

Fund assets 4,862 MSEK

Distribution per fund unit
Distribution date

Fund, date of launch 01.04.1984 Share class, date of 01.04.1984

Largest holdings

=ar goot moralingo	
AstraZeneca PLC	45.11%
Volvo AB Class B	5.31%
Hexagon AB Class B	4.10%
Assa Abloy AB Class B	4.09%
Skandinaviska Enskilda Banken AB Class A	3.96%
Essity AB Class B	3.54%
ABB Ltd	3.43%
Beijer Ref AB Class B	3.30%
Sandvik AB	2.70%
Autoliv Inc SEDR	2.64%

² Benchmark index: SIX SRI Sweden Index GI (60%), AstraZeneca (40%). The information in the table refers to the benchmark index valid at any given time. In the event the fund has previously had other benchmark indexes, this information can be found in the fund's annual report.

and the need to ensure delivery capacity. Declining gas prices in Europe and lower subsidies have dampened incentives for installing heating pumps. The inventory situation should be rebalanced during the end of the year and there is a further need for energy transition that is assisted by effective climate solutions over the long term. Sweco was weighed down by struggles in the UK market where projects within transport are being cancelled and the company is now adjusting after the overcapacity that arose.

The fund increased the holdings in Nolato, Astra Zeneca and Nibe during the quarter as well as took profits in Indutrade after strong stock performance. We decreased the holdings in SHB, Volvo and Atlas Copco during the quarter.

In the upcoming reporting period we will continue to focus on investee companies that have sustainable business models and competitive offers with sustainable growth even in a weaker economy.

As of: 26.04.2024

Historical yields are not a guarantee of future returns. A fund can both increase and decrease in value and it is not guaranteed that you will recover the entire invested amount. Note that a fund with risk level 5-7, as stated in the fund's fact sheet (KID), can vary greatly in value due to the fund's composition and management methodology. The prospectus, fund rules and KID are available under each fund. Summary of investors' rights.

The fund's fact sheet, risk level, fund rules and prospectus are available at www.handelsbanken.se/funds. Handelsbanken does not assume liability for any errors in the information.

www.handelsbanken.se/funds

Handelsbanken